Drug Trial Radar · NCT00750282
Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
422
Actual
Start
Aug 2008
Primary completion
Nov 2010
Study completion Nov 2010
Sponsor
- Lead sponsor
- Lantheus Biosciences Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 10, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to evaluate the efficacy, safety of a single dose of BAY 94-9172 (ZK 6013443) as an investigational medicinal product (IMP) in detecting cerebral protein-plaque (amyloid beta) with positron emission tomography (PET). IMP binds to amyloidal beta protein accumulating in brain tissue already from early stages of Alzheimer's disease (AD). IMP is therefore a potential tracer to be used for detecting amyloid plaques. For each subject it is required to visit the study centre during the screening phase, on the PET imaging day and for 1 follow-up visit on the next day. A telephone call for safety follow-up will be performed 7 days after IMP administration. During the screening phase the subject's medical, neurological and surgical history, specific laboratory tests related to AD, MRI of the brain and certain neuro-psychiatric tests will be performed. Clinical safety measures (physical examinations, vital signs, electrocardiogram (ECG) and laboratory tests) will be performed on the PET imaging day before IMP injection and monitored during and after two PET imaging sessions. Clinical safety measures will be performed again on the follow-up visit next day. The results of PET imaging with IMP will be compared between probable AD patients and healthy volunteers (HV). The clinical diagnosis is based on international validated and accepted criteria and established after comprehensive clinical and neuro-psychiatric examinations
Conditions
- Alzheimer Disease
- Amyloid Beta-Protein
Interventions
Florbetaben (BAY94-9172)Drug
Healthy volunteers and patients with probable Alzheimer's disease receiving single injection of investigational medicinal product BAY 94-9172 followed by subsequent PET imaging sessions
Primary outcomes
What the sponsor says the trial is designed to measure.
- Specificity and Sensitivity of Florbetaben PET Scans Obtained in Part A Using Two Separate Algorithms and the Onsite Clinical Diagnosis as the Standard of TruthTime frame: 90 - 110 min after investigational medical product (IMP) injection
- Specificity and Sensitivity of Florbetaben PET Scans Obtained in Part B Using Two Separate Algorithms and the Onsite Clinical Diagnosis as the Standard of Truth.Time frame: 90 - 110 min after IMP injection
Locations
23 sites in 5 countries. Site status is shown where the registry gives one.
Site not named
Sun City, Arizona
Site not named
Stanford, California
Site not named
New Haven, Connecticut
Site not named
New York, New York
Site not named
New York, New York
Site not named
The Bronx, New York
Site not named
Providence, Rhode Island
Site not named
Westmead, New South Wales, Australia
Site not named
Adelaide, South Australia, Australia
Site not named
Heidelberg, Victoria, Australia
Site not named
Erlangen, Bavaria, Germany
Site not named
München, Bavaria, Germany
Site not named
München, Bavaria, Germany
Site not named
Essen, North Rhine-Westphalia, Germany
Site not named
Jülich, North Rhine-Westphalia, Germany
Site not named
Münster, North Rhine-Westphalia, Germany
Site not named
Dresden, Saxony, Germany
Site not named
Leipzig, Saxony, Germany
Site not named
Berlin, State of Berlin, Germany
Site not named
Kobe, Hyōgo, Japan
Site not named
Kobe, Hyōgo, Japan
Site not named
Bunkyo-ku, Tokyo, Japan
Site not named
Zurich, Canton of Zurich, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.